Introduction
The transcription factor PU.1 has a crucial role during myeloid differentiation (Voso et al., 1994; Nerlov and Graf, 1998) . PU.1 is expressed at highest levels in granulocytic cells (Klemsz et al., 1990; Hromas et al., 1993; Chen et al., 1995; Back et al., 2005; Nutt et al., 2005) , and PU.1 À/À mice lack mature myeloid cells (Scott et al., 1994; McKercher et al., 1996; Anderson et al., 1998) . We recently reported that mutations of the PU.1 gene are found in some patients with acute myeloid leukemia (AML) (Mueller et al., 2002) and that PU.1 is suppressed in acute promyelocytic leukemia (Mueller et al., 2006) . Others have shown that loss and/or mutation of the gene encoding PU.1 contributes to radiation-induced murine AML (Cook et al., 2004; Suraweera et al., 2005) . PU.1 expression can be modulated by the balance of functional sense and antisense RNAs by a shared cis-regulatory element (Ebralidze et al., 2008) . Moreover, critically decreased PU.1 expression induces leukemia in mice (Rosenbauer et al., 2004) . In this context, an upstream regulatory element (URE) was identified to be able to confer myeloid-cell-specific enhancer activity in cell lines and transgenic mice (Li et al., 2001; Okuno et al., 2005) .
We here identified a novel nuclear factor-kB (NF-kB) binding site in the URE of PU.1. Interestingly, NF-kBmediated activation of the URE of PU.1 was repressed by polymorphisms of this site in four of 120 AML patients (3.3%). We therefore concluded that the expression of PU.1 can be suppressed in human leukemic cells by sequence alterations of an NF-kB binding site in the distal regulatory element of PU.1. These studies suggest that NF-kB can critically interfere with neutrophilic differentiation in leukemic cells.
Results
Two polymorphisms closely localized in the upstream regulatory element of PU.1 are observed more frequently in AML patients than in healthy individuals The URE of the human PU.1 gene is located on chromosome 11p at À17.3 to À16.2 kb upstream of the PU.1 transcription start site, and it consists of two highly conserved regions: a distal homology region (DHR) and a proximal homology region (PHR) (Figure 1a ; Okuno et al., 2005) . Here, we analysed the entire PU.1 URE by direct sequencing of DNA from 120 consecutive AML patients of all subtypes at diagnosis before initiation of treatment. The characteristics of the patients and healthy volunteers are shown in Table 1 .
We found in 4 out of 120 AML patients (3.3%) either one of two different polymorphisms within the DHR (Figure 1b) . The polymorphisms are presented in detail in Figure 2a . Both polymorphisms were not previously reported in single nucleotide polymorphism (SNP) databases (such as HapMap or others). They were heterozygous in all patients, and equally detectable in constitutive DNA from nonmalignant and nonhematopoietic tissues from all four patients. The first polymorphism was observed in only one patient (0.8%; patient #25), and it changed two base pairs-within four base pairsfrom cytidine to thymidine in the DHR at positions 46204360 and 46204357, with the numbering based on NIH reference sequence cNT009237.17, and subsequently encoded here as C60T/C57T.
The second polymorphism was detected in three AML patients (2.5%; patients #29, #76 and #135), and it was characterized by an insertion of a cytidine at position 46204357 (encoded as insC57). Sequencing of DNA from 141 healthy volunteers indicated that the C60T/ C57T polymorphism was not present in healthy controls, and that the insC57 polymorphism was observed in 1 out of 141 healthy controls (0.7%; Table 2 ). These results suggest that C60T/C57T and insC57 are polymorphisms in the DHR of PU.1 observed fivefold more frequently in AML patients as compared to normal individuals.
AML patients with C60T/C57T and insC57 have decreased PU.1 mRNA expression compared to AML patients with wild-type DHR sequences The upstream regulatory region URE with its DHR and PHR elements is critical for PU.1 expression. Consequently, we investigated whether the polymorphisms in the DHR affected PU.1 mRNA expression in AML patients. PU.1 mRNA expression was determined by quantitative real-time PCR in a cohort of 141 patients of all subtypes including the four patients with the C60T/ C57T and insC57, and all 120 AML patients screened for URE sequence alterations. We found that all AML patients with DHR polymorphisms expressed PU.1 mRNA levels below the standard deviation of their corresponding AML subtype (Figure 2b ). Unfortunately, no RNA was available from the one healthy individual with the insC57 polymorphism. These results suggest that AML patients with one of the two DHR polymorphisms have decreased PU.1 mRNA expression. 
Distal homology region
Figure 1 Localization of the C60T/C57T and the insC57 polymorphisms within a nuclear factor-kB (NF-kB) site in the distal homology region (DHR) of the upstream regulatory element (URE) of human PU.1. (a) Scheme of the homology region URE located 17 kb upstream of the PU.1 transcription start site on chromosome 11p11.2. The ruler depicts the distance from the PU.1 transcription start site in kilobases (kb). Arrow indicates direction of transcription. The URE is composed of a DHR and a proximal homology region (PHR) (Li et al., 2001; Okuno et al., 2005) . (b) Alignment of the DHR. Nucleotide positions of Homo sapiens (human) refer to previously published DHR numbering (Okuno et al., 2005) . Nucleotide positions for Rattus norvegicus (rat), Mus musculus (mouse), Canis familiaris (dog) and Felis catus (cat) are depicted and conserved nucleotides highlighted. The panel depicts the two DHR polymorphisms found. The first polymorphism encompasses 2 bp changes from cytidine to thymidine (C57 T) and (C60 T) at positions 46204357 and 46204360 (NIH reference sequence cNT 009237.17), and the second polymorphism is an insertion of a cytidine (insC57) (at position 46204357, NIH reference sequence cNT 009237.17).
NF-jB regulates PU.1 through a distal element N Bonadies et al A functional NF-kB binding site is affected by the DHR polymorphisms C60T/C57T and insC57 in AML patients The sequences in the DHR affected by the two polymorphisms indicated the presence of a putative NF-kB binding site. Spanning this site, we designed oligonucleotide probes for the wild-type sequence, the C60T/C57T polymorphism, the insC57 polymorphism and a mutation construct known to completely abolish NF-kB binding (DNF-kB). Electrophoretic mobility shift assays (EMSA) using the wild-type probe indicated that the NF-kB homodimer p50/p50 and the p50/p65 heterodimer were indeed binding to this sequence. In contrast, binding activity of the p65/p65 homodimer was not observed (Figure 3a ). This is consistent with previous reports indicating sequence-dependent binding affinities of the various NF-kB dimeric proteins (Kunsch et al., 1992; Ghosh et al., 1995; Nijnik et al., 2003) . As expected, the DNF-kB probe completely failed to bind NF-kB ( Figure 3b ). We therefore conclude that the site affected by the two polymorphisms is, indeed, part of a functional NF-kB binding site. Interestingly, EMSA studies using the C60T/C57T (Figure 3c ) and the insC57 (Figure 3d ) oligonucleotides suggested that the binding affinities of the NF-kB p50/ p50 homo-and the p50/p65 heterodimeric peptides to these sequences were not reduced compared to the wildtype sequence. Competition experiments with increasing amounts of unlabeled oligos suggested that the binding affinities to the polymorphic sequences even exceeded the affinities to the wild-type sequence. We observed a sixfold increase in the binding affinity of the heterodimeric p50/p65 complex for both polymorphisms by relative optical density (rOD/mm 2 ), whereas for the homodimeric p50/p50 peptides we found only a threefold increase for C60T/C57T and a fourfold increase for the insC57 (Figure 3e ). These results suggest that the two polymorphisms affect the relative binding affinities of both p50 and p65 homo-and heterodimers.
To ultimately assess the composition of the DNAprotein complex present at the DHR site of human PU.1 in vivo, chromatin immunoprecipitation (ChIP) experiments were performed in human myeloid leukemic U937 cells using specific NF-kBp50 and NF-kBp65 antibodies (Figure 3f ). Hereby, we confirmed that NF-kB p50 and NF-kB p65 are binding to the wild-type URE of PU.1 in U937 cells. Consistent with the EMSA experiments described above, the amount of p50 at this site exceeded p65 in the ChIP. In addition, binding activity of NF-kB p65 was not detectable in peripheral leukocytes from a healthy volunteer whereas p50 was detectable (Figure 3g) . A similar result was observed in two additional healthy individuals. Thus, NF-kB p50 binding appears to exceed NF-kB p65 binding to the wildtype sequence in the URE of PU.1. Interestingly however, myeloid cells from peripheral blood at remission of AML patient #135 with the insC53 mutation in the NF-kB site demonstrated preferential binding of the NF-kB p65. These data suggest that NF-kB binds to the URE of the PU.1 promoter also in vivo. Moreover, the binding affinities of the various NF-kB peptides are altered in myeloid cells of individuals with the insC57 polymorphism in the NF-kB site favoring binding of p65 NF-kB. We thus conclude that the binding affinities of the various NF-kB dimeric complexes are altered by the two polymorphisms as compared to the wild-type sequence, and that the polymorphic sequences are changing the composition of the dimeric NF-kB complexes present at this site.
NF-kB homo-and heterodimeric peptides differentially activate PU.1 expression Upstream regulatory element sequences were cloned into the pxp2 luciferase vector. We found that the basal transcriptional activity of the constructs including the entire URE sequence (DHR and PHR) mediated an up to 500-fold activation as compared to the empty pxp2 vector alone (Figure 4a ). This activation was mainly conferred by the PHR sequences. Remarkably, the basal activity of the construct with the URE alone (DHR and PHR) was twofold higher compared to the URE sequences added to the proximal promoter sequences (DHR and PHR and PRO) . Moreover, the basal activity of the URE sequences alone (DHR and PHR) was fourfold higher than the basal activity of the proximal promoter (PRO) alone. URE constructs containing either the C60T/C57T or the insC57 polymorphic sequence showed no differences in basal activity compared to the wild-type URE (data not shown). These results indicate that the URE alone mediates more potent baseline activation than the proximal promoter (PRO), and that this activation is not affected by the two DHR polymorphisms.
Consequently, we also analysed in transfection experiments the potential of the various NF-kB peptides to activate the URE. We observed that NF-kB p50 and p65 in a 1:1 ratio activated the URE up to 15-fold as compared to the empty pcDNA3 plasmid (Figure 4b ). Importantly, the PHR alone could not be activated by the NF-kB p50/p65 heterodimeric complex, whereas the DHR alone mediated an up to ninefold activation. We thus conclude that the heterodimeric p50/p65 NF-kB complex activated the URE of PU.1 primarily through the DHR sequences. Abbreviation: AML, acute myeloid leukemia.
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Finally, we tested the potential of the various NF-kB complexes to activate the URE of PU.1 (Figure 4c ). We observed that maximum activation of the URE construct was achieved with the NF-kB p50/p65 heterodimeric complex. In contrast, activation with NF-kB p50 alone was only 8% of the activation seen for p50/p65, and only 5% for p65 homodimers. This suggests that the p50/p65 heterodimer is the NF-kB complex predominantly able to activate the URE of the PU.1 gene.
Polymorphic NF-kB sequences detected in AML patients mediate decreased PU.1 activation and are deficient to synergistically activate PU.1 together with CEBPB We next investigated whether the polymorphic NF-kB sequences detected in AML patients affected PU.1 activation. We found that the activation of the insC57 construct-designated DHR2 in Figure 5a -by the NF-kB p50/p65 heterodimer was reduced by 40% compared to the wild-type URE construct. For the C60T/C57T construct-designated DHR1-we observed a reduction of 37%, and for a deletion construct known to abrogate NF-kB binding (DHRD; data not shown), a 44% reduction was observed. Again, neither the NF-kB p50 nor the p65 homodimers alone were able to mediate significant activation of the insC57 URE construct. The reduction in activation of the polymorphic insC57 and C60T/C57T sequences by p50/ p65 compared to the URE wild type was dose dependent as depicted in Figure 5b . These results suggest that the polymorphisms in the NF-kB site as detected in AML patients mediate decreased PU.1 activation. Expression levels of AML subtypes are represented as PU.1/GAPDH (glyceraldehyde-3-phosphate dehydrogenase) ratios and depicted as fold induction over the mean value of AML-M0 patients. Bars indicate standard deviation of expression levels of the patients of any AML subtype, the mean value of each subtype is represented by a single line. The red lines show the expression level of each patient with a polymorphic nuclear factor-kB (NF-kB) site. The red box on the right summarizes the mean expression level of all four AML patients with a polymorphic NF-kB sequence.
To assess the effect of differing p50/p65 ratios on URE activation, we transfected 4:1, 2:1, 1:1, 1:2 or 1:4 ratios of NF-kB p50 and p65 plasmids (Figure 5c ). We observed stronger URE activation if the ratio between the two NF-kB forms was balanced, whereas activation was decreasing if the ratio shifted in favor of one of the two forms. In summary, the exact ratio of the various NF-kB forms is crucial for PU.1 activation, and any change in either direction reduces URE activation.
We previously reported that CEBPB is specifically implicated in the activation of PU.1 in myeloid cells (Mueller et al., 2006) . We therefore analysed whether NF-kB-mediated activation of the URE is affected by CEBPB. We found that CEBPB alone did not significantly activate the wild-type URE construct (Figure 5d ). CEBPB together with either NF-kB p50 or p65 failed to mediate additional activation. However, if CEBPB was transfected together with equal amounts of both NF-kB p50 and p65 forms, a 2.1-fold increase in URE activation was observed as compared to NF-kB p50/p65-mediated activation. Notably, CEBPA and CEBPE activated the URE constructs significantly less efficiently than CEBPB (data not shown). We thus conclude that NF-kB and CEBPB synergistically activate the URE of PU.1.
Finally, the URE construct encoding the insC57 sequence (DHR2) mediated a 40% reduction, from 17.1-to 10.4-fold, if co-transfected together with CEBPB and with equal amounts of both NF-kB p50 and p65. For the C60T/C57T construct (DHR1), a reduction of 32% was observed. The activation of the polymorphic constructs turned out to be equal to the addition of the activation mediated by CEBPB and NF-kB alone (Figure 5e ). This suggests that the synergy between CEBPB and NF-kB in the activation of the URE is lost in the presence of the NF-kB polymorphic sequences.
Discussion
In this study, we identified a functional NF-kB binding site in a regulatory element 17 kb upstream of PU.1. Interestingly, we observed that NF-kB-mediated activation of PU.1 was repressed by changes of this site in 4 of 120 AML patients (3.3%). We therefore concluded that the expression of PU.1 can be suppressed in human leukemic cells by sequence alterations of a NF-kB binding site in this distal regulatory element of PU.1.
The variations were heterozygous and equally detectable at diagnosis, in remission samples as well as in nonhematopoietic tissues. Interestingly, both SNPs were localized within the DHR of the URE and affected a newly identified NF-kB binding site. Consequently, we were able to demonstrate that the heterodimeric NF-kB p50/p65 complex is activating PU.1 expression through this site, whereas the polymorphic NF-kB sequences mediated decreased activation of PU.1. These findings propose a model of how deregulated NF-kB-mediated activation of PU.1 might contribute to leukemogenesis in AML patients with one of these variations in the DHR of the URE. This conclusion is further supported by the finding that all four AML patients carrying one of these sequence variations had lower PU.1 mRNA expression than what could be expected from their AML subtype.
We found no evidence that fewer additional mutations are required in the SNP AML patients since we observed no difference in the mean age of onset of the disease in the SNP AML patients as compared to the wild-type patients (55 versus 57 years). Also, at least two of the four SNP AML patients had additional (different) cytogenetic abnormalities. Thus, it remains to be elucidated how exactly the constitutively present SNPs contribute to leukemogenesis in these patients. 
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Previous studies have identified a limited number of transcription factors regulating PU.1 expression through this URE. An LEF-1 site in the DHR of the URE was suggested to suppress PU.1 expression in combination with b-catenin (Rosenbauer et al., 2006) . Also, a PU.1 binding site in the PHR of the URE was reported to activate PU.1 in a self-regulatory manner (Okuno et al., 2005) . In addition, two CEBPA sites have NF-jB regulates PU.1 through a distal element N Bonadies et al been described in the PHR of the URE (Yeamans et al., 2007) , and three RUNX1/AML1 sites appear to be present in the PHR (Huang et al., 2008) . Our findings add NF-kB to this list of factors affecting activation of PU.1 expression through this distal regulatory element.
A recent report suggested that an SNP, different from the ones in this report in the DHR (rs10769263), occurred more frequently in the subset of AML patients with a complex karyotype. This SNP affects a binding site of the AT-rich sequence binding protein 1, leading to suppressed PU.1 expression (Steidl et al., 2007) . Remarkably, we observed a balanced distribution of this particular SNP among the various AML subtypes and also among healthy volunteers in our study. Given the rare occurrence of complex karyotype AML in our collection of AML patients (9%), a difference in the incidence of this SNP in this particular group might have remained undetectable.
NF-kB is a dimeric transcription factor that has been shown to regulate a rapidly growing number of target genes mainly related to stress-response, inflammation, growth and apoptosis. In addition, activation of the nuclear NF-kB pathway has been observed in a variety of cancers, including acute and chronic leukemias, and many types of lymphomas and in particular myeloma (Furman et al., 2000; Kordes et al., 2000) . Here, we observed that the affinity of p50/p65 was preferentially increased as compared to the p50/p50 homodimer, and thus the ratio between these two complexes was changed in favor of the p65-containing complexes. The NF-kB p50/p50 homodimeric complex is commonly believed to repress activation of the p50/p65 heterodimer as the p50 peptide lacks a transactivation domain, and as both dimers are competing for the same binding site (Schmitz and Baeuerle, 1991; Kunsch et al., 1992; Ghosh et al., 1995; Udalova et al., 2000; Nijnik et al., 2003) . However, in the particular context of the NF-kB site in the URE, we observed that p65/p65 homodimers equally failed to bind and activate this site. Thus, the NF-kB polymorphisms in the URE of PU.1 appear to critically alter a well-balanced ratio between p50 and p65 forms, which provides optimal activation through p50/p65 heterodimers whereas any changes favoring homodimeric binding appear to result in reduced binding and activation.
cis-Elements can affect gene expression by alternative promoters, enhancers or silencers, and their effects can vary according to the cellular context (Landry et al., 2003; Kleinjan and van Heyningen, 2005) . In our study, both homology regions of the URE (DHR and PHR) Figure 4 Upstream regulatory element (URE) mediates transcriptional activity, and the nuclear factor-kB (NF-kB) p50/p65 heterodimer activates PU.1 expression. (a) Basal activity of the pxp2 promoter constructs determined by luciferase reporter assays and transient transfections in COS-1 cells. pxp2 constructs (800 ng), containing either the wild-type DHR-PHR, PHR alone, distal homology region (DHR) alone, DHR-PHR-PRO together (URE-PRO), or PRO (proximal promoter region) alone were analysed. Activities are depicted as fold induction over 800 ng of pxp2. (b) Activation studies using 125 ng NF-kB p50 and 125 ng NF-kB p65. Activities of 400 ng of pxp2 constructs containing full-length URE (DHR-PHR), PHR alone, DHR alone and pxp2 alone were compared and depicted as fold induction over pcDNA3. (c) Activation potential of 250 ng (total amount of) NF-kB homo-and heterodimers. Activities of 400 ng of URE-pxp2 constructs are depicted as fold induction over pcDNA3.
NF-jB regulates PU.1 through a distal element N Bonadies et al were required for up to 30-fold NF-kB-mediated activation of PU.1. Remarkably, we found that the URE sequence of PU.1 mediated a strong activation of PU.1 even in constructs lacking the proximal promoter sequence (PRO). In fact, a slight decrease in PU.1 activation was observed if the URE was studied in combination with the proximal promoter. This suggests that the URE may exert true promoter function. We have recently reported that PU.1 expression is activated by CEBP family members-in particular CEBPB-through a site in the proximal PU.1 promoter (Mueller et al., 2006) . In addition, CEBPA was reported to bind to the PHR as well (Kummalue and Friedman, 2003; Hoogenkamp et al., 2007; Yeamans et al., 2007) . Here, we found that CEBPB alone activated the URE construct only about twofold. Notably however, we observed a synergistic URE activation of CEBPB in combination with NF-kB p50/p65, mediating a 14-fold induction. This effect was less pronounced with CEBPA or CEBPE. The basic ZIP domain of CEBP family members can interact with the Rel homology domain of NF-kB (Matsusaka et al., 1993; Stein et al., 1993; Friedman, 2007) , and cooperation of NF-kB p50 and CEBPA was shown to induce transcription of the oncoprotein BCL-2 (Paz-Priel et al., 2005). Our results of synergistic activation of the myeloid key transcription factor PU.1 through CEBPB and NF-kB further underline the importance of this interaction.
Our study points to a model in which a polymorphic NF-kB binding site deregulates the activating function of the URE thereby contributing to dysfunctional PU.1 expression and the development of AML. Our data imply that NF-kB in combination with CEBP family members is important during myeloid differentiation. Figure 5 The insC57 and the C60T/C57T polymorphisms negatively affect nuclear factor-kB (NF-kB) p50/p65-mediated activation and abolish the synergy of NF-kB with CEBPB. Luciferase assays in COS-1 cells with 400 ng of pxp2 constructs. (a) Activation of NF-kB p50/p65 heterodimer (250 ng of each) was compared to either NF-kB p50 or p65 homodimer alone (250 ng of each) or pcDNA3 (500 ng). Activities of 400 ng of wild-type upstream regulatory element (URE)-pxp2, URE2-pxp2 encoding insC57 (DHR2) and URE1-pxp2 encoding C60T/C57T (DHR1) are depicted as relative luminescence units (RLU). The scale is interrupted between 1000 and 4000. (b) Activation by NF-kB heterodimer with increasing amounts of expression plasmids NF-kB p50 or NF-kB p65 (31.25, 62.5, 125, or 250 ng of each plasmid). Activities are depicted as fold induction over 500 ng pcDNA3. Activities are depicted as fold induction over 500 ng pcDNA3 on wild-type URE-pxp2, URE2-pxp2 or URE1-pxp2. (c) Activation by differing ratios of NF-kB p50 and p65 expression plasmids. A total amount of 500 ng of NF-kB p50 and p65 expression plasmids was used in the following ratios: 4:1 (400:100 ng), 2:1 (333:167 ng), 1:1 (250 ng each), 1:2 (167:333 ng) and 1:4 (100:400 ng). Bars indicate standard deviations of three independent experiments. (d) Activation is shown of 400 ng of wild-type URE-pxp2, activated by NF-kB p50/p65 (62.5 ng of each subunit) together with CEBPB (125 ng), NF-kB p50/p65 alone (62.5 ng of each subunit), CEBPB (125 ng) together with either NF-kB p50 (62.5 mg), or NF-kB p65 (62.5 ng), and finally CEBPB alone (125 ng). Activities are depicted as fold induction over 500 ng pcDNA3. (e) Activation is shown of 400 ng of wild-type URE-pxp2, URE2-pxp2 or URE1-pxp2, transfected together with CEBPB (125 ng) and with NF-kB p50/p65 (62.5 ng of each subunit), NF-kB p50/p65 alone (62.5 ng of each subunit) and CEBPB alone (125 ng).
Concentrations of NF-kB p50/p65 were only 62.5 ng of each subunit, which is shown in (b) not to be sufficient to induce differences in activation.
NF-jB regulates PU.1 through a distal element N Bonadies et al
Constitutive expression of NF-kB has been reported in AML stem cells and was claimed to be responsible for maintenance of self-renewal capacity (Guzman et al., 2001) . Our data provide evidence that NF-kB alone and together with CEBPB affects PU.1 expression through the URE. Moreover, our study indicates that insertion of even a single base pair in a distal promoter element critically alters the tight regulation of an important tumor suppressor gene and thus might trigger the development of cancer. Bern, Switzerland, nos. 180/94, 162/2000 and 22/2001) .
Materials and methods

Homology analysis and alignment
PCR and sequencing
The following primer sequences have been used for the distal regulatory element (DHR): 5 0 -AGAGGAAACTGAGGCCA AGTG-3 0 and 5 0 -TGGCAGTCCTCACTGAGGCCATTG-3, and for the proximal regulatory element (PHR): 5 0 -CAA TGGCCTCAGTGAGGACTGCCA-3 0 and 5 0 -TCTTGGCG GAAGCTGTTAGGGAAG-3 0 . The PCR conditions were 94 1C for 5 min, followed by 35 cycles at 94 1C for 30 s, 60 1C for DHR or 52 1C for PHR for 45 s, and 72 1C for 1.5 min. PCR was performed with 100 ng of template DNA and Taq polymerase in 50 ml total reaction volume (Supermix, catalog no. 10572-014; Invitrogen Corporation). Products were analysed on 1% agarose gel electrophoresis and purified using QIAquick PCR Purification Kit (catalog no. 28106; Qiagen). Sequencing reactions were performed on an Applied Biosystems 3730 48-capillary DNA-Analyzer (Applied Biosystems, Foster City, CA, USA).
Quantitative real-time PCR of patient samples Primer pairs and fluorescent probes for PU.1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were for PU.1 (Hs 00231368 m1; Applied Biosystems) and GAPDH (4326317E-0403006; Applied Biosystems). cDNA was used for quantitative RT-PCR with TaqMan Universal PCR Master Mix (catalog no. 4304437; Applied Biosystems). The amplification cycles were 95 1C for 10 min, followed by 40 cycles with 95 1C for 15 s, 60 1C for 1 min and 72 1C for 1.5 min, and were performed on a 7900HT Sequence Detection System (Applied Biosystems). Expression levels were based on standard curves using SDS version 2.1 software (Applied Biosystems), and were normalized to GAPDH.
Electromobility shift assay 10E6 COS-1 cells were transfected with 3 mg expression plasmids of NF-kB p50, NF-kB p65 or both of them. After 48 h, cells were harvested and washed twice with phosphatebuffered saline (PBS). Cells were resuspended in buffer A (10 mM HEPES-KOH (pH 7.90), 1.5 mM MgCl 2 , 10 mM KCL, 1 mM DTT, 1 mM proteinase inhibitor), and incubated on ice for 15 min. Cells were then centrifuged (13 000 g for 20 s), and the supernatant was discarded. Pellets were resuspended in one-fifth of the initial volume in buffer C (20 mM HEPES-KOH (pH 7.90), 1.5 mM MgCl 2 , 420 mM NaCl, 25% glycerol, 0.2 mM EDTA, 1 mM DTT, 1 mM proteinase inhibitor), and incubated on slow rotation wheel at 4 1C for 30 min. After centrifugation at 13 000 g for 5 min, we stored the supernatant fraction containing nuclear proteins at À80 1C until analysis. Protein concentrations were assessed densitophotometrically by Bradford protein assay (catalog no. 500-0006; Bio-Rad, Hercules, CA, USA).
Oligonucleotides were annealed, labeled with [g-P 32 ]-ATP using T4 polynucleotide kinase (catalog no. 174645; Roche Diagnostics Corporation, Indianapolis, IN, USA), and purified on Sephadex column G50 (catalog no. 275330; Amersham, GE Healthcare Bio-Sciences Corporation, Piscataway, NJ, USA). The following oligonucleotides were used with the NF-kB binding site in capital letters and with the polymorphic sequences underlined: for DHR wild-type, 5 0 -ggagcacGGGC CTCCCCgggagtgggct-3 0 ; for the C60T/C57T polymorphism, 5 0 -ggagcacGGGTCTTCCCgggagtgggct-3 0 and for the insC57 polymorphism, 5 0 -ggagcacGGGCCTCCCCCgggagtgggct-3 0 . Also, a mutant oligonucleotide (DHRD) known to abolish NF-kB binding was used changing GGG to CTC: 5 0 -agcac CTCCCTCCCCgggagtg-3 0 (Tisne´et al., 1999). Nuclear extracts were incubated with radioactive probes for 30 min at room temperature in binding buffer containing 10 mM HEPES-KOH (pH 7.9), 50 mM KCL, 2.5 mM MgCl 2 , 1 mM DDT, 9% glycerol, 1 mg bovine serum albumin and 1 mg poly(dI-dC) (catalog no. 27788001; Amersham, GE Healthcare Bio-Sciences Corporation). Polyclonal rabbit antibody NF-kB p50 (catalog no. sc-7178X; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or NF-kB p65 (catalog no. sc-372X; Santa Cruz Biotechnology) were used for supershift analyses. For competition analyses, the unlabeled oligonucleotides wt, p1 and p2 were studied in 50-, 200-or 400-fold excess. Reaction mixtures were separated on a 4% polyacrylamide gel in 1ÂTBE buffer at 4 1C. Gels were dried and analysed by autoradiography. Quantitation of bands in relative optical densities (rOD/mm 2 ) was performed by VersaDoc Imaging System Model 3000 and analysed by Quantity One software (both from Bio-Rad).
Constructs
The DHR, the PHR, and the proximal promoter region of PU.1 (PRO) were cloned into the luciferase reporter plasmid pxp2.
Transient transfections and luciferase reporter assays
Transient transfections of COS-1 cells were performed using Lipofectamine reagent (catalog no. 18324-012; Invitrogen Corporation). A total of 250 000 cells per well were seeded into 12-well plates, and 400 ng pxp2 luciferase reporter constructs was transfected together with 0.125 ng pRL/CMVrenilla and expression plasmids. The total amount of transfected expression plasmids was adjusted to 500 ng with empty pcDNA3 plasmid. Luciferase activities were measured by a luminometer TD 20/20 (Promega Corporation, Madison, WI, USA). Relative luminescence units (RLU) represent firefly values normalized to renilla values. All transfection assays were repeated three times in independent experiments. The error bars in the transfection experiments indicate standard deviation.
Chromatin immunoprecipitation U937 cells were cultured in RPMI 1640 supplemented with 10% fetal calf serum (FCS). In addition, peripheral blood from one AML patient and from one healthy volunteer was used for ChIP. A total of 3 Â 10E7 peripheral blood mononuclear cells were purified by Ficoll separation, and cultured for 2 h in RPMI 1640 supplemented with 20% FCS. U937 cells or vital mononuclear blood cells were cross-linked with 0.5% formaldehyde before incubation in 0.125 M glycine. Cells were washed twice with PBS and lysed in lysis buffer supplemented with 5 mM phenylmethylsulfonyl fluoride (PMSF), and 5 mg/ml leupeptin and aprotinin. The nuclei were lysed in nuclei lysis buffer supplemented with 5 mM PMSF, 5 mg/ml of leupeptin and aprotinin. The chromatin was sonicated eight times for 20 s and incubated with Protein G Agarose beads. The supernatant was treated either with 6 mg NF-kB p50 antibody, 6 mg NF-kB p65 antibody (NF-kB p50 antibody: catalog no. sc7178 and NF-kB p65 antibody: catalog no. sc372; Santa Cruz Biotechnology), 2 mg mouse IgG, 2 mg RNA Polymerase II mouse antibody (catalog no. 53001-53007; Active Motif, B-1330 Rixensart, Belgium). The lysate-antibody mixture was then incubated with 100 ml Protein G Agarose beads. Pellets were washed once with ChIP IP buffer (catalog no. 53001-53007; Active Motif), two times with Wash Buffer 1 (catalog no. 53001-53007; Active Motif) supplemented with PMSF, leupeptin and aprotinin, once with Wash Buffer 2 (catalog no. 53001-53007; Active Motif) supplemented with PMSF, leupeptin and aprotinin and once with Wash Buffer 3 (catalog no. 53001-53007; Active Motif). The DNA-protein antibody complexes were eluted and 1 ml RNAse and 4 ml 5 M NaCl were added before treatment with proteinase K. DNA was resuspended in 50 ml water and 5 ml was used for PCR analysis using the following primers to amplify the NF-kB binding site in the URE of PU.1: sense 5 0 -GCCATGAAATGCTCTGC TCTCT-3 0 and antisense 5 0 -GTCACTCACCTCTTGCTTC TGG-3 0 . Control PCR primers for the RNA Polymerase II site of the GAPDH promoter were: sense 5 0 -TACTAGCGG TTTTACGGGCG-3 0 , and antisense 5 0 -TCGAACAGGAG GAGCAGAGAGCGA-3 0 . As a positive control for NF-kB binding, the promoter region of the IL-8 gene was amplified with sense 5 0 -GGGCCATCAGTTGCAAATC-3 0 and antisense 5 0 -TTCCTTCCGGTGGTTTCTTC-3 0 . PCR products were analysed by electrophoresis on a 1% agarose gel.
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